Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

Phase 1 Terminated 88 enrolled Chinook Therapeutics, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.

Timeline

Start: 2022-04-08
Primary completion: 2023-04-19
Completion: 2023-04-19

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Publications

Cox JH, Boily MO, Caron A, Sheng T, Wu J, Ding J, Gaudreault S, Chong O, Surendradoss J, Gomez R, Lester J, Dumais V, Li X, Gumpena R, Hall MD, Waterson AG, Stott G, Flint AJ, Moore WJ, Lowther WT, Knight J, Percival MD, Tong V, Oballa R, Powell DA, King AJ. Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment. J Am Soc Nephrol. 2025 Apr 7;36(8):1535-1547. doi: 10.1681/ASN.0000000690.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CHK336	Small molecule	15 mg	Oral
Subject	CHK336	Small molecule	30 mg	Oral
Subject	CHK336	Small molecule	60 mg	Oral
Subject	CHK336	Small molecule	125 mg	Oral
Subject	CHK336	Small molecule	500 mg	Oral

Indications

No indication recorded.